{"id":"W2162901058","doi":"10.1016/s1470-2045(15)00051-0","title":"Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial","year":2015,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":306,"is_retracted":false,"has_abstract":false,"ca_institutions":"Translational Research in Oncology","funders":"Novartis Pharmaceuticals Corporation","keywords":"Everolimus; Medicine; Trastuzumab; Internal medicine; Metastatic breast cancer; Breast cancer; Oncology; Response Evaluation Criteria in Solid Tumors; Paclitaxel; Placebo; Cancer; Clinical trial; Phases of clinical research; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005748689,0.0003049814,0.001211539,0.00009925956,0.0001130246,0.0000143358,0.0002047997,0.0001496041,0.00007479532],"category_scores_gemma":[0.0001144201,0.0001683835,0.0001074245,0.0002730631,0.0002982128,0.00009537329,0.00003652272,0.0002469804,0.000008672566],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002357972,"about_ca_system_score_gemma":0.001936211,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001101335,"about_ca_topic_score_gemma":0.001900824,"domain_scores_codex":[0.9976958,0.0002616312,0.0004490196,0.0004166292,0.0005957697,0.0005811722],"domain_scores_gemma":[0.9972435,0.0006641244,0.0003778719,0.0004516557,0.0009928999,0.0002699285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.956636,0.005636608,0.001340232,0.0001130174,0.0006347123,0.00002785308,0.003187894,0.0005460073,0.00002694526,0.0000484198,0.0004918771,0.03131044],"study_design_scores_gemma":[0.9290218,0.0624731,0.001024094,0.0002464417,0.0006221152,0.0000349666,0.0006053229,0.0007358648,0.000687454,0.00004291158,0.004324549,0.0001813266],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9764553,0.0002112183,0.0003019031,0.008558732,0.0003009627,0.01274836,0.0005373681,0.00004644609,0.0008397009],"genre_scores_gemma":[0.994077,0.0002305842,0.0004911964,0.0003071333,0.0005470011,0.003631137,0.00027538,0.00005668483,0.0003839034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05683649,"threshold_uncertainty_score":0.686648,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1072753189955495,"score_gpt":0.4374998133184536,"score_spread":0.330224494322904,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}